Results for quarter ended 30-Jun-26

Q1FY27 results (unaudited): Consolidated: Revenue 4.9bn +55% y-y (3.2bn) EBITDA 1.7bn +61% y-y (1.0bn) EBITDA margin 33.8% (32.5%) +130 bps y-y PAT 0.57bn +3% y-y (0.55bn) FY26 results (audited, restated): Standalone: Revenue 114.2bn +34% y-y (85.4bn) EBITDA 28.1bn +39% y-y (20.2bn) EBITDA margin 24.6% (23.7%) +90 bps y-y PAT 20.3bn +40% y-y (14.5bn) Consolidated: Revenue 138.9bn +36% y-y (102.3bn) EBITDA 33.6bn +38% y-y (24.3bn) EBITDA margin 24.2% (23.7%) +50 bps y-y PAT 19.6bn +39% y-y (14.1bn) Dividend: None stated Commentary: The quarter includes the effect of the amalgamation of J.B. Chemicals & Pharmaceuticals Limited with an appointed date of 21 January 2026, accounted using pooling of interest method. Exceptional items include regulatory fees, inventory write-off due to fire incident, and severance compensation related to restructuring.